Docket No.: 0480-0165PUS1

AMENDMENT TO THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

1. - 9. (Canceled)

10. (Currently amended) A method for treating cancer caused by cells expressing melanotransferrin (p97) at their surface, said method comprising the step of administering to a patient in need thereof exogenous soluble p97 or an antibody, or active fragment thereof, directed to said p97 expressed on the surface of said cell, said soluble p97 or active fragment thereof competing with the p97 expressed on the cell surface, activating plasminogen in solution instead of membrane-bound plasminogen, thus preventing cell migration , said antibody, or active fragment thereof binding p97 on the surface of the cell thus preventing activation of membrane-bound plasminogen, preventing cell migration, and preventing cancer cells from spreading.

- 11. 13. (Canceled)
- 14. (Original) The method of claim 10, wherein said cell is a tumor cell.
- 15. (Original) The method of claim 10, wherein said cell is selected from the group consisting of human vascular or microvascular endothelial cells and human melanoma cells.
 - 16. 31. (Canceled)
- 32. (Currently amended) A pharmaceutical composition for use in treating cancer comprising a therapeutically effective amount of one of melanotransferrin (p97), or an enzymatically active fragment thereof, or an antibody recognizing specifically p97, or an antigen binding fragment thereof, in association with a pharmaceutically acceptable carrier.
 - 33. 35. (Canceled)

Application No. 10/556,145 Reply to Office Action dated July 7, 2008

36. (Original) A method of treating cancer, comprising administering to an individual a therapeutically effective amount of a pharmaceutical composition according to claim 32.

Docket No.: 0480-0165PUS1

- 37. (Currently amended) $\underbrace{\text{T}}_{\text{he}}$ method according to claim 36, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intravenously, intraperitoneally, intraarterially, transdermally or via a mucus membrane.
- 38. (Previously presented) The method according to claim 36, wherein said cancer is selected from the group consisting of melanoma, prostate cancer, leukemia, hormone dependent cancer, breast cancer, colon cancer, lung cancer, skin cancer, ovarian cancer, pancreatic cancer, bone cancer, liver cancer, biliary cancer, urinary organ cancer (for example, bladder, testis), lymphoma, retinoblastoma, sarcoma, epidermal cancer, esophageal cancer, stomach cancer, cancer of the brain, cancer of the kidney, and metastasis thereof.

39. - 54. (Canceled)

3 DRN/II